Ray Dorsey
@RayDorsey7
Followers
587
Following
4K
Statuses
2K
Neurology Pharmacist (Consultant). MS team. NHS veteran. Mum, occasional runner.
London, England
Joined March 2013
RT @TheNeuroAcademy: The #MultipleSclerosis Foundation MasterClass 2025 is booking up quickly! This is an ideal introduction to MS as a spe…
0
2
0
@karenlhillman @Roddy_Neilson @gmcuk This was an error by the comms team which appears to have been corrected
2
0
1
RT @joelamathews: Cohort 3 masterclass 1 completed. It was an inspiring couple of days seeing how far we have come as #neuropharmacists. Lo…
0
2
0
RT @TheNeuroAcademy: Our 3rd Neuropharmacy MasterClass is underway! Over 20 pharmacists from across the UK have joined us for two days of e…
0
2
0
Looking forward to co-chairing our 3rd Neuropharmacy Masterclass with @joelamathews @TheNeuroAcademy. Over 20 pharmacists from around the UK attending today and tomorrow to learn more about treatment of neurological conditions @UKCPANeuro @UKNeuroPharmacy #neuropharmacy
0
2
14
RT @ImperialPeople: "Using antimicrobials responsibly is important now and for future generations." To start WAAW, we spoke to Priti Kukad…
0
8
0
RT @tarunyaarun: We are appointing a consultant neurologist with specialist interest in MS and neuroinflammation to join our vibrant and ex…
0
17
0
RT @bart_professor: Fox Rob (US): tolebrutinib vs placebo in nrSPMS (HERCULES trial) - 6m CDP: 31% decreases risk on tolebr - 3m CDP: 24% “…
0
8
0
RT @KaarinaKowalec: Was so cool to be part of the @ECTRIMS late breaking session today and share our results on depression genetic burden a…
0
3
0
RT @bart_professor: Riley Bove (US) showed that treatment with Ocrelizumab during lactation is SAFE! Negligible transfer in the milk and no…
0
23
0
RT @DrJNicholas: Chataway: STAT-2 trial showed no benefit of simvastatin in slowing disability progression in #SPMS #ECTRIMS2024
https://t.…
0
6
0
RT @bart_professor: Jiwon Oh (US): tolebrutinib vs teriflunimode in RRMS (GEMINI trials). - ARR : no difference! - 6m CDW: 29% reduction on…
0
9
0
The #neuropharmacy team @ImperialNHS are proud to have 2 e-posters on display @ECTRIMS in Copenhagen. Looking at our #MS cohorts on B Cell therapies #ECTRIMS2024
0
0
10
RT @drbarrysinger: Frexalimab 2 extension data up to 72 weeks demonstrates robust impact on enhancing lesions and relapses with favorable s…
0
7
0
Great to finally have results of an RCT looking at benefit of vitamin D in MS. 100,000 units every 2 weeks reduced risk of new disease activity in CiS patients @UKCPANeuro @UKNeuroPharmacy
#ECTRIMS2024
Thouvenot (Fr) D-Lay MS study with vitamin D (100k IU/14d) in CIS. Showing 34% risk reduction of new disease activity vs placebo! Proof of a safe and effective treatment in MS! Certainly in CIS and in patients with low vit D already! Use it as ADD-ON R/! 👏🏻👏🏻 #ECTRIMS2024
1
1
5
RT @drbarrysinger: Bove: SOPRANINO study. Ocrelizumab Ocrevus was undetectable in blood of infants being nursed by mothers with MS being tr…
0
23
0
Great to see a poster from #Neuropharmacist Charles-Henry Her & the Swansea MS team @ECTRIMS. Looking at effect of B Cell Tx on Ig levels in their cohort. Check it out! (P822) Opportunity for @UKCPANeuro to collaborate & pool data for next year? #ECTRIMS2024 @UKNeuroPharmacy
0
0
1
RT @drbarrysinger: Zipp: #CAR-T is a potential new treatment for multiple sclerosis #MS by deeply depleting B cells in the central nervous…
0
24
0
Reassuring to see some data telling us that 90% patients keep their immune protection against VZV & measles after starting B cell therapies . Small sub group of pts drop their VZV Ig. #ECTRIMS2024 @ECTRIMS @UKCPANeuro @UKNeuroPharmacy
0
2
2